Get the Stockscreener App
3.61
26.89%
0.765
Kala Bio Inc stock is traded at $3.61, with a volume of 955.10K.
It is up +26.89% in the last 24 hours and up +33.21% over the past month.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$2.845
Open:
$2.85
24h Volume:
955.10K
Relative Volume:
9.90
Market Cap:
$67.11M
Revenue:
$420.00K
Net Income/Loss:
$-26.98M
P/E Ratio:
-0.8653
EPS:
-4.1721
Net Cash Flow:
$-32.01M
1W Performance:
+46.15%
1M Performance:
+33.21%
6M Performance:
-87.52%
1Y Performance:
-98.30%
1-Day Range:
$2.85
$3.66
1-Week Range:
$2.4701
$3.66
52-Week Range:
$2.03
$1,030.00
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.61 | 67.11M | 420.00K | -26.98M | -32.01M | -4.1721 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
KALA BIO Inc (KALA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KALA BIO Inc (KALA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KALA BIO Inc (KALA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KALA BIO Inc (KALA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KALA BIO Inc (KALA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
KALA BIO Inc (KALA) Institutional Confidence - TradingKey
KALA BIO Inc (KALA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KALA BIO Inc (KALA) Valuation: PE, PB & Fair Value Analysis - TradingKey
KALA BIO Inc (KALA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
KALA BIO Inc. Surges 6.5% as Biotech Momentum Builds: Testing Key Resistance at $2.76Resistance Breakout Stocks - newsline.com
KALA Q4 2025 Earnings: Narrowed Loss Drives 6.5% Stock GainQuarterly Earnings Report - newsline.com
KALA BIO (NASDAQ: KALA) registers $350M shelf; 1-for-50 reverse split recorded - Stock Titan
KALA BIO Inc. (KALA) Holds Steady Near Support Amid Minimal Price MovementMoving Average Ribbon - newsline.com
KALA BIO (KALA) Holds Steady Near $2.39 Amid Tight Trading RangeUpthrust Pattern - newsline.com
KALA BIO Surges 11%: Approaching Key Resistance at $2.40Wave Truncation - newsline.com
KALA BIO INC (KALA) Stock Chart - ChartMill
KALA Stock Price, Quote & Chart | KALA BIO INC (NASDAQ:KALA) - ChartMill
KALA BIO Q4 2025 Earnings: Wider-Than-Expected Loss but Narrower EPS Surprise Drives Mixed Sentiment - newsline.com
Net margin % of KALA BIO, Inc. – LSX:A4243T - TradingView
KALA BIO Shares Slide Over 6% Amid Light Trading and Sector PressureVolatility Term Structure - newsline.com
KALA BIO (KALA) Smashes Q4 2025 Views with $-33.50 EPSNegative Surprise Momentum - thelegaladvocate.com
KALA BIO (KALA) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-33.50Free Cash Flow Trends - newsline.com
Kala Bio (FRA:27F) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2026) - GuruFocus
Red Light Holland Corp (OP: TRUFF - FinancialContent
KALA stock hits record low – firm announces reverse split after shares fail to surpass the $1 mark - MSN
KALA BIO (KALA) files 13G/A: Baker Bros. reports 2,312 shares post-split - Stock Titan
KALA BIO, Inc. 1Q 2026: Net loss $(1.6M), Diluted EPS $(0.14) — 10-Q Summary - TradingView
KALA BIO: Q1 Earnings Snapshot - 10TV
KALA: Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions - TradingView
KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KALA BIO (NASDAQ: KALA) slashes R&D spend and pivots to Researgency AI platform - Stock Titan
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Total assets of KALA BIO, Inc. – LSX:A4243T - TradingView
Discontinued operations of KALA BIO, Inc. – TRADEGATE:27F - TradingView
Cash from operating activities of KALA BIO, Inc. – FWB:27F - TradingView
Asset turnover of KALA BIO, Inc. – FWB:27F - TradingView
Working capital per share of KALA BIO, Inc. – FWB:27F - TradingView
Price to book ratio of KALA BIO, Inc. – FWB:27F - TradingView
KALA BIO, Inc. Balance Sheet – TRADEGATE:27F - TradingView
Discontinued operations of KALA BIO, Inc. – LSX:A4243T - TradingView
Dilution adjustment of KALA BIO, Inc. – GETTEX:27F - TradingView
KALA BIO, Inc. Balance Sheet – LS:A4243T - TradingView
KALA BIO, Inc. Balance Sheet – GETTEX:27F - TradingView
Discontinued operations of KALA BIO, Inc. – FWB:27F - TradingView
Enterprise value to EBITDA ratio of KALA BIO, Inc. – FWB:27F - TradingView
KALA BIO, Inc. Earnings and Revenue – MUN:27F - TradingView
Why Kala Bio’s Stock Is Sinking Again - TipRanks
CapEx per share of KALA BIO INC. O.N. – MUN:27F - TradingView
EBIT per share of KALA BIO INC. O.N. – MUN:27F - TradingView
Free cash flow per share of KALA BIO INC. O.N. – MUN:27F - TradingView
Long term debt to total equity ratio of KALA BIO INC. O.N. – MUN:27F - TradingView
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):